Skip to main content
Premium Trial:

Request an Annual Quote

BioForce Nanosciences Receives NIDDK Grant for NanoArrays

NEW YORK, April 15 - BioForce Nanosciences of Ames, Iowa, has received a $500,000 Phase I SBIR grant from the National Institute of Diabetes, Digestive, and Kidney diseases to build an antibody nanoarray for diagnostic tests using small sample volumes, the company said today.


This award, "Protein Nanoarray for Cytokine Profiling in Mouse Models", is one of  many SBIR grants that BioForce has received. Last July, the company was awarded a Phase II grant to further develop its nanoarray technology.


The company also has a collaboration with the NCI-FDA clinical proteomics program to develop nanoarrays. BioForce can currently fit a thousand spots within the space of a single ordinary microarrays spot.


Under this grant, the company will develop nanoarrays for protein profiling of cytokine biomarkers in diabetes, progressive renal failure, inflammatory bowel disease, and other kidney and digestive system diseases.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.